Altmetric

2023 FDA TIDES (peptides and oligonucleotides) Harvest

File Description SizeFormat 
pharmaceuticals-17-00243.pdfPublished version2.62 MBAdobe PDFView/Open
Title: 2023 FDA TIDES (peptides and oligonucleotides) Harvest
Authors: Al Shaer, D
Al Musaimi, O
Albericio, F
De la Torre, BG
Item Type: Journal Article
Abstract: A total of nine TIDES (pepTIDES and oligonucleoTIDES) were approved by the FDA during 2023. The four approved oligonucleotides are indicated for various types of disorders, including amyotrophic lateral sclerosis, geographic atrophy, primary hyperoxaluria type 1, and polyneuropathy of hereditary transthyretin-mediated amyloidosis. All oligonucleotides show chemically modified structures to enhance their stability and therapeutic effectiveness as antisense or aptamer oligomers. Some of them demonstrate various types of conjugation to driving ligands. The approved peptides comprise various structures, including linear, cyclic, and lipopeptides, and have diverse applications. Interestingly, the FDA has granted its first orphan drug designation for a peptide-based drug as a highly selective chemokine antagonist. Furthermore, Rett syndrome has found its first-ever core symptoms treatment, which is also peptide-based. Here, we analyze the TIDES approved in 2023 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects.
Issue Date: Feb-2024
Date of Acceptance: 9-Feb-2024
URI: http://hdl.handle.net/10044/1/113138
DOI: 10.3390/ph17020243
ISSN: 1424-8247
Publisher: MDPI
Journal / Book Title: Pharmaceuticals (Basel)
Volume: 17
Issue: 2
Copyright Statement: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Publication Status: Published
Conference Place: Switzerland
Article Number: 243
Online Publication Date: 2024-02-13
Appears in Collections:Chemical Engineering



This item is licensed under a Creative Commons License Creative Commons